Entera Bio Ltd. Ordinary Shares
Veridion Score
Composite trend over time
Why is ENTX moving today?
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ENTX.
ENTX insider activity
Entera Bio Ltd. Ordinary Shares
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ENTX.
ENTX contract awards, year to date.
Public federal awards linked to this ticker.
ENTX lobbying filings, year to date.
Registered lobbying filings matched to Entera Bio Ltd. Ordinary Shares.